Core Insights - IQVIA Holdings Inc. is recognized as one of the best affordable growth stocks to buy now, with an Outperform rating and a price target of $221 set by RBC Capital [1][2] Group 1: Company Progress and Capabilities - The company is making significant strides in clinical trial activity and is expected to benefit from advancements in contract research organization and data analytics capabilities [2] - IQVIA holds over 64 petabytes of data and has established relationships with large pharmaceutical companies, which is seen as a critical differentiator in the market [2][3] Group 2: Technological Integration and Acquisitions - The integration and adoption of artificial intelligence in life sciences are anticipated to further enhance the company's outlook [3] - IQVIA has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories, which includes five sites for in vitro discovery services [3] Group 3: Industry Positioning - IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, focusing on improving healthcare outcomes through data, technology, and human expertise [4]

Group 1 - IQVIA Holdings Inc. is considered a strong buy in the healthcare sector, with recent price target adjustments from various firms following its fiscal Q4 report [1][2] - Mizuho reduced its price target for IQVIA from $266 to $215 while maintaining an Outperform rating, and Truist lowered its target from $290 to $245, updating their models due to re-segmentation after Q4 earnings [1] - TD Cowen cut its price target from $245 to $174, maintaining a Hold rating, and noted that while AI risks exist, their long-term impact on Contract Research Organizations (CROs) is not fully understood [2] Group 2 - IQVIA Holdings provides advanced analytics, clinical research services, and technology solutions specifically for the life sciences industry, with operations divided into three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions [3]

Core Insights - IQVIA Holdings Inc. is a healthcare research services provider valued at $28 billion, offering analytics, technology solutions, and clinical research services to the life sciences industry [1] Performance Overview - IQV's shares have underperformed the broader market, declining 11.4% over the past year, while the S&P 500 Index has increased by nearly 12.3% [2] - In 2026, IQV's stock fell 24.1%, contrasting with the marginal rise of the S&P 500 on a year-to-date basis [2] Comparative Analysis - Compared to the Health Care Select Sector SPDR Fund (XLV), which gained about 9.1% over the past year, IQV's performance has been notably weaker, with the ETF's 1.9% returns year-to-date outpacing IQV's double-digit losses [3] Financial Performance - IQV's underperformance is attributed to margin compression and concerns regarding the sustainability of gains, despite acquisitions that expanded capabilities [6] - In Q4, IQV reported an adjusted EPS of $3.42, exceeding Wall Street expectations of $3.40, with revenue of $4.4 billion surpassing forecasts of $4.2 billion [7] - For the full year, IQV expects adjusted EPS in the range of $12.55 to $12.85 and revenue between $17.2 billion and $17.4 billion [7] Future Projections - Analysts project IQV's EPS to grow by 6.9% to $11.56 on a diluted basis for fiscal 2026 [8] - The company's earnings surprise history is mixed, with three out of the last four quarters beating consensus estimates [8] - Among 22 analysts covering IQV stock, the consensus rating is a "Strong Buy," supported by 16 "Strong Buy" ratings, one "Moderate Buy," and five "Holds" [8]

Core Insights - IQVIA Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry, headquartered in Durham, North Carolina [1] - The company has a market capitalization of $41.28 billion and operates across several countries, assisting pharmaceutical, biotechnology, and medical device companies through its core segments [2] Financial Performance - Analysts expect IQVIA to report a profit of $3.13 per share on a diluted basis for Q4 fiscal 2025, representing a year-over-year increase of 7.9% [4] - For the full fiscal year 2025, diluted EPS is expected to grow by 5.3% annually to $10.79, followed by an 8.7% improvement to $11.73 in fiscal 2026 [4] Stock Performance - Over the past 52 weeks, IQVIA's stock has gained 18.5%, while over the past six months, it has gained 48% [5] - In comparison, the broader S&P 500 Index has increased by 19.7% and 11.5% over the same periods, indicating that IQVIA has underperformed the broader market over the past year but outperformed over the past six months [5] Sector Comparison - The State Street Health Care Select Sector SPDR ETF has gained 12.7% over the past 52 weeks and 16.4% over the past six months, showing that IQVIA has outperformed its sector during these periods [6] Strategic Partnerships - Last month, IQVIA announced a partnership with Amazon Web Services (AWS), designating AWS as its Preferred Agentic Cloud Provider, which includes the provision of IQVIA's AI platform on AWS to enhance healthcare analytics [7]

Core Insights - IQVIA Holdings Inc. is valued at $37.6 billion and provides healthcare research services, including analytics, technology solutions, and clinical research to the life sciences industry, aimed at improving healthcare outcomes for patients [1] Performance Overview - Over the past year, IQV shares have gained 12.2%, underperforming the S&P 500 Index, which increased by nearly 13.7% [2] - In 2025, IQV's stock rose 10%, while the S&P 500 saw a 13.4% rise on a year-to-date basis [2] - Compared to the Health Care Select Sector SPDR Fund (XLV), which gained about 7% over the past year, IQV's performance is relatively better, although the ETF's 10.3% year-to-date returns outshine IQV's gains [3] Financial Results - For Q3, IQV reported an adjusted EPS of $3, exceeding Wall Street expectations of $2.96, and revenue of $4.10 billion, beating forecasts of $4.07 billion [4] - The company expects full-year adjusted EPS to be in the range of $11.85 to $11.95 and revenue between $16.2 billion and $16.3 billion [4] Analyst Expectations - Analysts project IQV's EPS to grow by 5.1% to $10.77 for the current fiscal year ending in December [5] - Among 22 analysts covering IQV, the consensus rating is a "Strong Buy," with 16 "Strong Buy" ratings, one "Moderate Buy," and five "Holds" [5] - A month ago, the bullish sentiment increased, with 15 analysts suggesting a "Strong Buy" [6] Price Targets - BMO Capital initiated coverage of IQV with an "Outperform" rating and a price target of $260, indicating a potential upside of 20.3% from current levels [6] - The mean price target is $244.38, representing a 13.1% premium to current prices, while the highest price target of $265 suggests an upside potential of 22.6% [6]

Company Overview - IQVIA Holdings Inc. has a market cap of $32.2 billion and is a leading global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry [1] - The company operates through four segments: Technology & Analytics Solutions, Research & Development Solutions, Contract Sales & Medical Solutions, and Contract Sales & Medical Solutions [1] Market Position and Growth Potential - IQVIA is classified as a "large-cap" stock and is positioned for steady growth due to its diverse offerings and strong backlog, with digital health and AI trends providing long-term tailwinds [2] - The company has a consensus rating of "Strong Buy" from 22 analysts, with a mean price target of $213.52, indicating a potential upside of 16.1% from current market prices [6] Stock Performance - Shares of IQVIA have decreased 25.9% from their 52-week high of $248.03, but have surged 15.1% over the past three months, outperforming the Langar Global Healthtech ETF's (LGHT) 1.3% decrease [3] - Year-to-date, IQVIA's stock has declined 6.4%, lagging behind LGHT's marginal rise, and over the past 52 weeks, shares have plunged nearly 21.8%, compared to LGHT's 2.3% drop [4] Recent Financial Results - On July 22, IQVIA shares jumped 17.9% following the release of Q2 results, with adjusted EPS of $2.81 exceeding Wall Street's estimate of $2.76, and revenue of $4.02 billion surpassing expectations of $3.96 billion [5] - The company guided for full-year adjusted EPS between $11.75 and $12.05 and revenue in the range of $16.1 to $16.3 billion [5] Competitive Landscape - Top rival Agilent Technologies, Inc. has seen its shares fall 7.6% year-to-date and 10.1% over the past 52 weeks, which is a greater decline than IQVIA's performance during the same timeframe [6]